Resp Care
-
Randomized Controlled Trial Comparative Study
Nocturnal oxygenation using a pulsed-dose oxygen-conserving device compared to continuous flow.
The pulsed-dose oxygen-conserving device (PDOCD) has gained wide acceptance as a tool to reduce the cost and inconvenience of portable oxygen delivery. Despite the widespread use of PDOCDs in awake and ambulating patients, few studies report their use during sleep. This study was designed to compare heart rate and oxygen saturation (measured via pulse oximetry [S(pO2)]) of sleeping patients using one brand of PDOCD versus continuous-flow oxygen. ⋯ The PDOCD model we studied was able to deliver oxygen therapy (via nasal cannula) comparable to continuous-flow in 9 of 10 patients. The resting daytime S(pO2) on continuous-flow appears to be an appropriate target for setting the PDOCD to ensure adequate oxygenation, even during sleep, with the PDOCD we tested. We conclude that the PDOCD we tested is able to maintain adequate S(pO2) during sleep in selected patients. Because of differences in design, triggering-signal sensitivity, and oxygen-pulse volume, these results cannot be generalized to all patients or all oxygen-conserving devices. Further research is needed to determine the general performance of PDOCDs on larger populations of oxygen-dependent patients and patients with sleep-disordered breathing.
-
Randomized Controlled Trial Comparative Study
Work of breathing during lung-protective ventilation in patients with acute lung injury and acute respiratory distress syndrome: a comparison between volume and pressure-regulated breathing modes.
Pressure-control ventilation (PCV) and pressure-regulated volume-control (PRVC) ventilation are used during lung-protective ventilation because the high, variable, peak inspiratory flow rate (V (I)) may reduce patient work of breathing (WOB) more than the fixed V (I) of volume-control ventilation (VCV). Patient-triggered breaths during PCV and PRVC may result in excessive tidal volume (V(T)) delivery unless the inspiratory pressure is reduced, which in turn may decrease the peak V (I). We tested whether PCV and PRVC reduce WOB better than VCV with a high, fixed peak V (I) (75 L/min) while also maintaining a low V(T) target. ⋯ During lung-protective ventilation, PCV and PRVC offer no advantage in reducing WOB, compared to VCV with a high flow rate, and in some patients did not allow control of V(T) to be as precise.
-
Randomized Controlled Trial Comparative Study
Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis.
We hypothesized that aerosol distribution in the lungs of patients with cystic fibrosis changes with positive expiratory pressure (PEP). ⋯ These results indicate that less aerosol is deposited in the lungs of patients with cystic fibrosis when the Pari LC Plus nebulizer is used with the Pari PEP device, as described in these experiments. Nevertheless, aerosol administration with this nebulizer and PEP device also results in a proportional redistribution of aerosol to the peripheral airways, compared to nebulization without the PEP device. The clinical relevance of this subtle redistribution of aerosol in cystic fibrosis patients will probably depend on the drug administered and disease severity.
-
Randomized Controlled Trial
Effects of expiratory rib-cage compression on oxygenation, ventilation, and airway-secretion removal in patients receiving mechanical ventilation.
Expiratory rib-cage compression, a chest physiotherapy technique, is well known as the "squeezing" technique in Japan. ⋯ This study suggests that rib-cage compression prior to endotracheal suctioning does not improve airway-secretion removal, oxygenation, or ventilation after endotracheal suctioning in this unselected population of mechanically ventilated patients.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Positive expiratory pressure device acceptance by hospitalized children with sickle cell disease is comparable to incentive spirometry.
The pulmonary complication in sickle cell disease known as acute chest syndrome (ACS) has potential for high morbidity and mortality. A randomized trial demonstrated that incentive spirometry (IS) reduces the rate of ACS, leading to a role for respiratory therapy in hospital management of sickle cell pain. However, use of IS can be limited by chest wall pain, or by difficulty with the coordinated inspiration in a young child. Intermittent positive expiratory pressure (PEP) therapy may be easier for a child's coordination and more comfortable than IS for a child with chest wall pain. ⋯ These preliminary results show no difference in the primary outcomes in the 2 groups. Intermittent PEP therapy warrants further study as an alternative to IS for sickle cell patients at high risk for ACS, as effective preventive respiratory therapy.